Back
Day Range
$33.02
$38.00
52-Week Range
$15.49
$38.06
Volume
200
50D / 200D Avg
$34.65
/
$29.90
Prev Close
$33.02
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (626 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 2.9 | 0.4 |
| P/B | 1.5 | 2.9 |
| ROE % | 71.4 | 3.7 |
| Net Margin % | 51.1 | 3.9 |
| Rev Growth 5Y % | 204.7 | 10.0 |
| D/E | 0.0 | 0.2 |
Analyst Price Target
No analyst coverage available
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2030 |
$0.00
$0.00 – $0.00
|
5.9 B | 0 |
| FY2029 |
$25.26
$15.23 – $38.31
|
4.5 B | 1 |
| FY2028 |
$6.68
$4.03 – $10.14
|
2.4 B | 1 |
Key Takeaways
Revenue grew 204.66% annually over 5 years — strong growth
ROE of 71.38% indicates high profitability
Net margin of 51.14% shows strong profitability
Debt/Equity of 0.04 — conservative balance sheet
Negative free cash flow of 0.0
P/E of 2.87 — trading at a low valuation
Growth
Revenue Growth (5Y)
204.66%
Revenue (1Y)674.85%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
71.38%
ROIC50.31%
Net Margin51.14%
Op. Margin68.44%
Safety
Debt / Equity
0.04
Current Ratio4.78
Interest Coverage36.10
Valuation
P/E Ratio
2.87
P/B Ratio1.49
EV/EBITDA1.44
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 674.85% | Revenue Growth (3Y) | 79.92% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | 110.91% |
| Revenue Growth (5Y) | 204.66% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 1.99B | Net Income (TTM) | 1.02B |
| ROE | 71.38% | ROA | 39.70% |
| Gross Margin | 97.04% | Operating Margin | 68.44% |
| Net Margin | 51.14% | Free Cash Flow (TTM) | 0.0 |
| ROIC | 50.31% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0.04 | Current Ratio | 4.78 |
| Interest Coverage | 36.10 | Dividend Yield | 0.00% |
| Valuation | |||
| P/E Ratio | 2.87 | P/B Ratio | 1.49 |
| P/S Ratio | 1.47 | PEG Ratio | -0.04 |
| EV/EBITDA | 1.44 | Dividend Yield | 0.00% |
| Market Cap | 2.93B | Enterprise Value | 1.96B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.99B | 257.35M | 616.00M | 228.29M | 23.15M |
| Net Income | 1.02B | -177.08M | 229.25M | -11.18M | -119.79M |
| EPS (Diluted) | 11.52 | -2.00 | 2.59 | -0.13 | -1.36 |
| Gross Profit | 1.94B | 230.37M | 526.37M | 153.97M | -31.92M |
| Operating Income | 1.36B | -228.51M | 252.64M | -17.44M | -139.72M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 2.57B | 1.11B | 1.19B | 858.31M | 897.73M |
| Total Liabilities | 606.62M | 216.74M | 139.50M | 72.07M | 109.05M |
| Shareholders' Equity | 1.96B | 894.94M | 1.05B | 786.24M | 788.68M |
| Total Debt | 72.24M | 54.23M | 4.98M | 10.04M | 15.88M |
| Cash & Equivalents | 1.04B | 512.93M | 611.57M | 805.39M | 848.41M |
| Current Assets | 2.48B | 1.01B | 1.15B | 820.84M | 861.79M |
| Current Liabilities | 519.47M | 175.66M | 124.97M | 70.88M | 101.27M |
Strategy Scores
This stock passed the criteria for 3 strategies
Score = fit strength (0–100)
Rank = position among all matches
Recent Activity
Entered
Capital Heavy Grower
Mar 24, 2026
Entered
Contrarian Investing (David Dreman)
Mar 24, 2026
Entered
Value Investing (Warren Buffett)
Mar 24, 2026